Heka.Bio

HekaBio is accelerating access to medicines and MedTech in premium global markets, starting with Japan

[Heka.Bio @heka_bio]

📢 Meet HekaBio at CPHI Korea 2026
We're pleased to share that our CEO, Rob Claar will be speaking at CPHI Korea 2026 in Seoul.

Learn more about Japan's healthcare market, business development opportunities, and successful partnership approaches.

📍 COEX, Seoul
📅 August 25-27, 2026

We look forward to connecting with industry leaders and innovators from across the region.
hashtag#CPHIKorea hashtag#JapanMarketEntry hashtag#Biotech hashtag#Pharma hashtag#HekaBio

[Heka.Bio @heka_bio]

Our CEO, @robclaar, recently shared his perspective on leadership in an interview that explores the intersection of science, decision‑making, and people.
The discussion reflects how thoughtful, evidence‑based leadership is essential in regulated industries such as medical devices.

https://t.co/f6B3ALLrj4

[Heka.Bio @heka_bio]

当社CEOの Rob Claar が 日経バイオテク の取材を受け、HekaBio K.K.のミッションや、日本およびアジアにおける革新的なヘルスケアソリューションの推進に対する考えを語っています。https://t.co/1bKW3MZDP5

[Heka.Bio @heka_bio]

HekaBio featured in Nikkei Biotech!

Our CEO Rob Claar was interviewed by Nikkei Biotech, sharing perspectives on HekaBio K.K.’s mission and our approach to advancing innovative healthcare solutions in Japan and across Asia.
A thoughtful read for anyone interested in the evolving biotech and medtech landscape in the region.https://t.co/5k31HDstJc

[Heka.Bio @heka_bio]

HekaBioとAlpha Tau Medical、固形腫瘍治療機器「Alpha DaRT システム」が日本で製造販売承認を取得https://t.co/CaSanG7mBQ

[Heka.Bio @heka_bio]

🎉 We’re proud to announce that Alpha DaRT (Diffusing Alpha Radiation Therapy) has received regulatory approval in Japan, marking the first approval outside of Israel for this innovative solid tumor treatment.
HekaBio led the approval process and will be responsible for launching Alpha DaRT in Japan, bringing a new treatment option for patients with unresectable or recurrent head and neck cancer.
A meaningful milestone for patients, clinicians, and our teams.
#medtech #innovation #Cancer
https://t.co/IcwK13G5wg

[Heka.Bio @heka_bio]

💡 JPM26で見えた4つのインサイト
当社CEOのRob ClaarとCFOのDeron Wolfeは、先日サンフランシスコで開催された J.P. Morgan Healthcare Conference 2026（JPM26） に参加しました。
JPMは世界のバイオテック・ヘルスケア分野で最も影響力のあるイベントの1つであり、現地での活発な議論や熱気は、業界の現状ととくに日本における新たな機会を再認識させてくれるものでした。

1.   ディールへの楽観ムード
サンフランシスコの晴れやかな雰囲気の中、今週のキーワードは「楽観」でした。ライセンス契約件数は過去最高、M&Aも増加、プライベート投資は回復傾向、株式市場での資金調達も堅調で、IPO環境も開きつつあります。
今年中にディールをまとめたいという熱量はどの会合でも感じられ、私たちも同じ気持ちです。
また、当社 HekaBio K.K. にとっても絶好のタイミングで、Series Bの資金調達を開始し、日本での商業活動も本格化しています。

2.広がるAI活用の実装フェーズ
投資がAI企業に集中した“ハイプ期”は終わり、より実務的で幅広いAI活用が進んでいる印象を受けました。
HekaBioでは、毎年200件以上の導入候補技術をスクリーニングしデューデリジェンスを行うプロセスを効率化するためにAIを活用しています。今後は、がんや神経変性疾患領域の臨床試験における患者特定・組み入れにもAIソリューションを採用していく予定です。

3.臨床開発で存在感を増す中国
臨床開発のスピード、コスト効率、アセットの質という点で、中国市場への注目が一段と高まっています。実際、ライセンス契約価値において、中国はすでに米国を上回る存在となっています。
JPMを通じて、私たちも中国由来のアセットをより積極的に検討する必要性や、日米中を含むマルチリージョン臨床試験への参加を一層強化すべきだと感じました。追加コストをかけずに複数の承認を同時に目指せる点は大きなメリットです。

4.日本市場のポテンシャル拡大
JPM26でも、米国のバイオテックやMedTech企業に対し、日本市場の価値を数多く議論しました。今年は例年以上に関心が高まっており、観光体験や日本文化に対する好意だけではなく、より実務的な理由からの興味が増えています。
たとえば、日本医療研究開発機構（AMED）による大規模な非希薄化型の助成金への関心や、細胞治療を一定条件下で承認前に自費診療として提供できる再生医療安全性確保法（ASRM）についての問い合わせが多く寄せられました。
日本は薬機法上の“ドラッグ・デバイスラグ”解消に向け、規制の合理化を継続しており、海外企業にとっても魅力的な市場機会が広がっています。

日本に関するご質問があれば、ぜひお気軽にお声がけください。

[Heka.Bio @heka_bio]

4 Insights from San Francisco: Our CEO, Rob Claar, and CFO, Deron Wolfe, recently attended the J.P. Morgan Healthcare Conference 2026 (JPM26) in San Francisco, one of the most influential gatherings in global biotech and healthcare. The energy and discussions there sparked several reflections on the state of our industry and the opportunities emerging, especially for Japan.

1. Optimism for Deals
Optimism was the word of the week in sunny San Francisco. Licensing deals are at an all-time high; M&A is up; private funding is recovering; public financing is very strong and the IPO window is expected to open. Everyone we met was enthusiastic to get their deals done in 2026, and so are we!

The timing is excellent for us at HekaBio K.K. as we’ve just opened our Series B fundraising and are initiating commercial activities in Japan.

2. AI Realism
We seem to have emerged beyond the period of hype when only AI companies could attract investment. At the same time, we have more practical applications of AI available for a broad range of development and business processes.

At HekaBio K.K., our primary use case is streamlining our filtering and diligence of the 200+ innovations we analyze each year for in-licensing consideration. Coming up, we will also employ solutions for patient identification and enrollment for clinical trials in oncology and neurodegeneration.

3. China Resurgence
The focus is now on China for the remarkable speed and cost performance of clinical development, and for the quality of assets. China has now surpassed the US as the leading source of worldwide licensing value.

We came out of JPM feeling a need to sharpen our focus on China for asset opportunities and for inclusion in multi-regional clinical trials. It makes a lot of sense to synchronize a US, Japan and China trial in order to seek multiple approvals without adding cost.

4. Japan Opportunities
We are always talking to US-focused emerging biopharma and MedTech companies about the value of Japan, and JPM26 was no different. There does seem to be more interest in Japan this year, and it’s not only coming from cultural appreciation or positive tourist experiences.

There is more awareness of and curiosity about the availability of large scale non-dilutive grants from the Japan Agency for Medical Research and Development (AMED). We also had people ask us about the Act on the Safety of Regenerative Medicine (ASRM) which enables some cell therapy programs to launch under patient-pay prior to regulatory approval under certain conditions.

Japan continues its efforts to deregulate and rationalize in order to solve the drug and device lag, which opens up attractive opportunities for overseas companies. If you have questions on Japan, we would be happy to hear from you.

We wish everyone an impactful and rewarding 2026!

#JPM26 #Biotech #LifeSciences #HealthcareInnovation #LicensingDeals #AIinHealthcare #JapanBiotech #ClinicalTrials #MedTech #HekaBio

[Heka.Bio @heka_bio]

NKGen Biotech and HekaBio Enter Strategic Partnership to Bring Novel NK Cell Therapy to Japan https://t.co/xdoa52U8z9

[MedTech World @Med_Tech_World]

🌏 #MTWHongKong2025 brings MedTech leaders to Asia’s innovation hub:

Marion Zammit – Chief Foreign Direct Investment Specialist, @maltaenterprise
Landon Lack – CEO, MedConnect China
Rodney Kelly – CGO, HekaBio

🗓️ June 30–July 1
🚀Register now: https://t.co/04klWKsj8Z

[前田雄樹｜AnswersNews編集長 @answers_news]

【6月17日】AnswersNews朝刊ポスト🗞️

🔎製薬業界 今朝の注目ニュース
▽アルフレッサHD、ドラッグ・ラグ/ロス解消へ2社と提携
▽アクセリードとエイツーヘルスケア、医薬品の研究開発支援で提携

詳しくは👇
https://t.co/TZC1wi5YvI

[Heka.Bio @heka_bio]

アルフレッサHD、ドラッグ・ラグ/ロス解消へ2社と提携 など｜製薬業界きょうのニュースまとめ読み（2025年6月16日） https://t.co/fzoIwt8TWK #AnswersNews

[Heka.Bio @heka_bio]

HekaBio, Japan-based Biopharma and MedTech Platform, Enters Strategic Partnership with Alfresa Holdings Corporation - https://t.co/uqMyAVt8j3

[Rob Claar @robclaar]

Good news for Alpha Tau! https://t.co/FYS8jgb8mP